| Literature DB >> 35565671 |
Anna Zawistowska-Rojek1,2, Stefan Tyski1,2.
Abstract
The proper functioning of the human organism is dependent on a number of factors. The health condition of the organism can be often enhanced through appropriate supplementation, as well as the application of certain biological agents. Probiotics, i.e., live microorganisms that exert a beneficial effect on the health of the host when administered in adequate amounts, are often used in commonly available dietary supplements or functional foods, such as yoghurts. Specific strains of microorganisms, administered in appropriate amounts, may find application in the treatment of conditions such as various types of diarrhoea (viral, antibiotic-related, caused by Clostridioides difficile), irritable bowel syndrome, ulcerative colitis, Crohn's disease, or allergic disorders. In contrast, live microorganisms capable of exerting influence on the nervous system and mental health through interactions with the gut microbiome are referred to as psychobiotics. Live microbes are often used in combination with prebiotics to form synbiotics, which stimulate growth and/or activate the metabolism of the healthy gut microbiome. Prebiotics may serve as a substrate for the growth of probiotic strains or fermentation processes. Compared to prebiotic substances, probiotic microorganisms are more tolerant of environmental conditions, such as oxygenation, pH, or temperature in a given organism. It is also worth emphasizing that the health of the host may be influenced not only by live microorganisms, but also by their metabolites or cell components, which are referred to as postbiotics and paraprobiotics. This work presents the mechanisms of action employed by probiotics, prebiotics, synbiotics, postbiotics, paraprobiotics, and psychobiotics, together with the results of studies confirming their effectiveness and impact on consumer health.Entities:
Keywords: paraprobiotic; postbiotic; prebiotic; probiotic; psychobiotic; synbiotic
Mesh:
Substances:
Year: 2022 PMID: 35565671 PMCID: PMC9103441 DOI: 10.3390/nu14091700
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Biological factors that can affect the health of the host.
| Name | Definition | References |
|---|---|---|
| Probiotics | live microorganisms that, when administered in adequate amounts, confer a health benefit on the host | [ |
| Prebiotics | a substrate that is selectively utilized by host microorganisms conferring a health benefit | [ |
| Synbiotics | a mixture comprising of live microorganisms and substrate(s) selectively utilized by host microorganisms that confers a health benefit on the host | [ |
| Postbiotics | preparation of inanimate microorganisms and/or their components that confers a health benefit on the host | [ |
| Paraprobiotics | non-viable microbial cells (either intact or broken), or crude cell extracts, which, when administered (orally or topically) in adequate amounts, confer a benefit on the human or animal consumer | [ |
| Psychobiotics | probiotics that confer mental health benefits to the host when consumed in a particular quantity through the interaction with commensal gut bacteria | [ |
Probiotic microorganisms [22,23,24,25,26].
| Genus | Species |
|---|---|
|
| |
|
| |
|
| |
|
| |
| Other |
* Name according to Zheng et al., 2020 [27].
Examples of the activity of probiotics confirmed in scientific research.
| Disease | Probiotic Strains/Duration of | Effects of Activity | References |
|---|---|---|---|
| Rheumatoid arthritis |
improvement of the DAS-28 (Disease Activity Score) reduction in insulin level | [ | |
| Irritable bowel syndrome |
reduction in abdominal pain severity mitigation of IBS symptoms | [ | |
|
reduction in the severity of IBS symptoms, reduction in the level of interleukin-6 (IL-6) and tumour necrosis factor-α (TNF-α) reduction in the number of bacteria: | [ | ||
| Ulcerative colitis |
reduction in intestinal inflammation | [ | |
| Infant colic |
reduction in the duration of colic in the group receiving probiotic in comparison to the group receiving placebo | [ | |
| Biochemical, oxidative and inflammatory markers |
an increase in the level of total antioxidant capacity (T-AOC) reduction in malondialdehyde (MDA) level an increase in the level of interleukin-10 (IL-10) and tumour necrosis factor-α (TNF-α) lowering the expression of an increase in the expression of | [ | |
| Chronic |
reduction in the frequency of defecation significant increase in acetic and propionic acid content change in the diversity of the gut microbiome-reduction in the quantity of | [ | |
| Antibiotic associated diarrhea |
reduction in the incidence of diarrhoea reduction in the duration of diarrhoea | [ | |
|
reduction in the incidence of diarrhoea | [ | ||
| Gastrointestinal symptoms |
mitigation of general symptoms (abdominal pain and flatulence) a significant increase in the level of | [ | |
| Atopic dermatitis |
lower SCORAD (Scoring Atopic Dermatitis) values in children lower levels of IL-4, IFN-γ and IL-17 IgE level did not change significantly | [ | |
|
lower SCORAD values in the group of children aged from 12 months to 13 years lower number of eosinophils, reduction in IFN-γ and IL-4 level | [ | ||
|
lower SCORAD score in adults lower levels of IL-4, IFN-γ and IL-17 higher levels of IFN-γ and Foxp3+ | [ |
Figure 1Examples of the most commonly used prebiotics [8,33,67,68,69]; FOS—fructooligosaccharides; GOS—galactooligosaccharides; IMO—isomaltooligosaccharides; TOS—transgalactooligosaccharides; XOS—xylooligosaccharides; SBOS—soybean oligosaccharides; MOS—mannanoligosaccharides.